昂利康股价涨5倍后又跌掉4成 拟定增募资11.6亿元

Core Viewpoint - The company, Anglikang, plans to raise 116 million yuan through a private placement of A-shares to fund its innovative drug research and industrialization projects [1][3]. Fundraising Details - The total investment for the innovative drug research and industrialization project is 119.56 million yuan, with the company intending to use 116 million yuan from the raised funds [3]. - The issuance will be priced at no less than 80% of the average stock price over the 20 trading days prior to the issuance date [4]. - The number of shares to be issued will not exceed 30% of the total shares before the issuance, amounting to a maximum of 60,518,455 shares [4]. Shareholder Structure - The issuance will involve up to 35 qualified investors, including securities investment funds, securities companies, and qualified foreign institutional investors [4]. - After the issuance, the controlling shareholder, Shengzhou JunTai, will hold 27.26% of the company, while the actual controllers, Fang Nanping and Lü Huizao, will hold 4.25% and 2.77% respectively, leading to a diluted control of 34.27% [5]. Financial Performance - In 2024, the company reported a revenue of 1.54 billion yuan, a decrease of 5.41% year-on-year, and a net profit attributable to shareholders of 80.33 million yuan, down 41.94% [8][9]. - For the first three quarters of 2025, the company achieved a revenue of 1.06 billion yuan, a decline of 5.92%, but the net profit attributable to shareholders increased by 55.59% to 78 million yuan [9][10].